Table 1. Gene expression of wild-type survivin, survivin-2B, and survivin-deltaEx3 in 134 NSCLCs according to clinical characteristics.

		Wild-type survivin		Survivin-2B		Survivin-deltaEx3
Variables	n	Standardised gene expression ratio	P-value	Standardised gene expression ratio	P-value	Standardised gene expression ratio	P-value
Tumour status
T1	46	1.407±0.786	0.3145	1.472±1.094	0.6335	0.922±0.614	0.3219
T2	48	1.475±0.698		0.985±0.515		0.884±0.526
T3	22	1.817±0.885		1.345±0.747		1.189±0.720
T4	18	1.646±0.905		1.144±0.681		1.063±0.638
Nodal status
N0	86	1.459±0.835	0.1613	1.265±0.748	0.5628	0.902±0.564	0.0781
N1, N2, N3	48	1.660±0.707		1.175±0.914		1.096±0.673
Pathological stage
Stage I	60	1.385±0.819	0.0558	1.281±0.796	0.5626	0.833±0.512	0.0174
Stage II, III	74	1.649±0.759		1.194±0.860		1.084±0.661
Differentiation
Well	34	1.288±0.712	0.0383	1.318±0.832	0.4964	0.743±0.526	0.0110
Moderately or poorly	100	1.614±0.807		1.203±0.832		1.049±0.619
Histology
Adenocarcinoma	66	1.362±0.664	0.0181a	1.192±0.736	0.5191a	0.854±0.587	0.0377a
Squamous cell carcinoma	65	1.690±0.892		1.285±0.923		1.075±0.616
Large cell carcinoma	3	1.780±0.570		0.850±0.507		1.321±0.620
Total	134	1.531±0.795		1.233±0.830		0.971±0.610

Abbreviation: NSCLCs=non-small cell lung cancers.

^aSquamous cell carcinoma vs adenocarcinoma.